Skip to main content

Table 6 Logistic regression analysis predicting a last PSA value of <0.2 ng/mL in patients with a normal testosterone level at the last follow-up (after at least 4 years)

From: Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer

  univariate multivariate
variables OR 95%C.I. P-value OR 95%C.I. P-value
IMRT (reference) vs. BT 9.840 5.681–17.041 <0.001 5.032 1.911–13.253 0.001
PSA -10 ng/mL reference      n.s.
10-20 ng/mL 0.766 0.459–1.277 0.306    
20 ng/mL- 0.202 0.096–0.426 <0.001    
BED -160Gy2 reference    reference   
160-180Gy2 7.040 3.546–13.977 <0.001 2.753 1.017–7.450 0.046
180Gy2- 8.038 4.800–13.459 <0.001 2.859 1.184–6.903 0.020
Age −64 reference    reference   
65–74 1.666 1.017–2.730 0.043 2.679 1.524–4.709 0.001
75- 1.498 0.819–2.742 0.190 2.956 1.444–6.053 0.003
Risk (D’Amico) Low reference      n.s.
Intermediate 0.982 0.604–1.597 0.941    
High 0.445 0.255–0.778 0.004    
ADT use none reference      n.s.
Neoad+ 0.729 0.450–1.183 0.201    
Ad+ 0.290 0.070–1.197 0.087    
Neoad+/Ad+ 0.326 0.175–0.610 <0.001    
  1. OR odds ratio, C.I confidential interval, IMRT intensity modulated radiation therapy, BT brachytherapy, PSA prostate specific antigen, BED biological effective dose, ADT androgen deprivation therapy, Neoad neoadjuvant, Ad adjuvant